The African Giant's Playbook: Can Zimbabwe Replicate Egypt’s Pharmaceutical Export Miracle?

Harare, Zimbabwe – With an annual pharmaceutical import bill exceeding US$300 million and a market dominated by foreign suppliers, Zimbabwe is confronting a stark economic and health security reality: it cannot afford to remain a net importer of medicines. 

The country imports between 60% and 70% of its medicinal requirements, a dependency that drains foreign currency and leaves the public health system vulnerable to supply chain disruptions. For an economy seeking upper-middle-income status by 2030, the path to pharmaceutical self-sufficiency is no longer optional—it is existential.

The imperative for local production is underscored by the sheer scale of the opportunity. Zimbabwe’s pharmaceutical market is estimated at between US$404 million and US$450 million, yet only 12% of medicines are produced locally, according to official estimates. The bulk of the market—over US$250 million—is sustained by donor agencies, while private imports dominate the retail segment.

This reliance on external funding and foreign supply exposes the country to the vagaries of international aid flows and global price fluctuations, a vulnerability that has concentrated minds in government and industry alike.

Despite these challenges, progress is being made. The locally-made share of essential medicines has more than doubled from 15% to 36% over the past five years, while the number of pharmaceutical companies has risen from nine to 14. Capacity utilisation has surged from a mere 12% in 2020 to 51%, signalling that the domestic industry is gaining traction. 

Yet, even with this growth, Zimbabwe still imports US$220 million worth of medicines annually—a figure the government is determined to slash by at least US$100 million by the end of 2025 through targeted policy interventions.

At the heart of this transformation is the Medicines Control Authority of Zimbabwe (MCAZ), which has adopted World Health Organization (WHO) cGMP standards as the regulatory backbone for the sector. 

The MCAZ regularly updates localized framework resources, including the MCAZ Guidelines for Good Manufacturing Practice (MCAZ-LED-GL-09) and its addendums for classifying manufacturing deficiencies. 

These guidelines, effective December 2025, provide a clear roadmap for both prospective and licensed manufacturers to achieve compliance, ensuring that "Zimbabwean-made" on a medicine packet becomes a guarantee of quality.

The government is backing regulatory rigor with financial firepower. A Pharmaceutical Revolving Fund is being established to provide affordable financing for the industry, while VAT zero-rating on pharmaceutical products has been reinstated. 

The Sugar Content Tax, now bringing in more than US$30 million a year, is being prioritised to enhance financial support for the production of essential medicines. These measures are designed to level the playing field against cheap imports from China and India, which currently threaten the viability of local manufacturers.

The push for local consumption is also being driven by state procurement. The government has committed to ensuring sustained uptake of locally produced drugs by public agencies and the private sector, while NatPharm—the National Pharmaceutical Company—is being reformed and capacitated to serve as both a strategic procurement hub and a direct manufacturer. 

NatPharm plans to establish two manufacturing plants outside Harare, aiming to increase local production to 60% by 2030 from less than 30% in 2024.

Beyond meeting domestic demand, Zimbabwe is positioning itself as a regional exporter. The country is centrally positioned to supply pharmaceuticals to over 200 million people across the Southern African Development Community (SADC) region.

Local manufacturer Varichem Pharmaceuticals is already exporting to Botswana, South Africa and Zambia, while a joint venture with Iran promises to produce unique drugs not currently manufactured locally, further expanding export capacity. Drug makers estimate that US$45 million in investment could unlock access to the US$3 billion SADC pharmaceutical market.

The template for this ambition is already visible elsewhere on the continent. Egypt, once heavily reliant on medicine imports, has transformed itself into Africa’s pharmaceutical gateway. By the end of 2025, Egypt’s pharmaceutical market reached approximately 4 billion packs valued at EGP 422 billion (US$8.48 billion). 

Pharmaceutical exports reached approximately US$1.3 billion by the end of 2025, with a target of US$3 billion by 2030. Egypt achieved WHO Maturity Level 3 for medicines and vaccines, has 183 licensed pharmaceutical factories, and has secured partnerships with global players like Bayer to localise production of essential medicines.

For Zimbabwe, the lesson is clear: regulatory excellence, strategic investment and export orientation are the pillars of a successful pharmaceutical industry. 

With the MCAZ pursuing WHO Global Benchmarking Tool Maturity Level 4 status—having reportedly achieved 99.8% compliance in its internal self-assessment—the foundation is being laid. 

The question is no longer whether Zimbabwe can build a competitive pharmaceutical sector, but how quickly it can replicate the Egyptian model and turn its geographic advantage into a thriving export industry. The clock is ticking, and the stakes could not be higher.